RxDoctor Payments Data

Habib Doss, MD

Hematology & Oncology · Nashville, TNNPI 1174565543

Payments from drug & device makers

$19,425in general payments, 2019–2025

Across 565 payments — averaging $34.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Karyopharm Therapeutics Inc.$2K
  • Johnson & Johnson$2K
  • Beigene USA, Inc.$1K
  • AVEO Pharmaceuticals, Inc.$1K
  • Rigel Pharmaceuticals, Inc.$1K
  • Novartis$1K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$3,83820%
  • Speaking & faculty fees$3,07516%
  • Food & beverage$11,95962%
  • Education$5533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Karyopharm Therapeutics Inc.4$2,045
Johnson & Johnson28$1,543
Beigene USA, Inc.5$1,416
AVEO Pharmaceuticals, Inc.8$1,385
Rigel Pharmaceuticals, Inc.10$1,380
Novartis52$1,076
Merck33$903
AstraZeneca(2 entities)39$850
Eli Lilly1$500
E.r. Squibb & Sons, L.L.C.33$492
Amgen22$449
Bristol Myers Squibb18$431
Gilead(2 entities)13$373
Daiichi Sankyo Inc.15$358
Seagen Inc.11$345
Astellas Pharma US Inc17$336
AbbVie11$330
Genentech USA, Inc.15$330
Eisai Inc.9$315
Regeneron Healthcare Solutions, Inc.11$299
Pfizer20$278
Bayer14$264
Sanofi12$252
Incyte Corporation10$230
Takeda Pharmaceuticals U.S.A., Inc.9$211
Exelixis Inc.10$207
Pharmacyclics LLC, An Abbvie Company10$184
Pharmaessentia USA Corporation7$177
GSK7$173
Taiho Oncology, Inc.7$167
Array Biopharma Inc8$156
Stemline Therapeutics Inc.2$135
Lilly USA, LLC9$119
EMD Serono, Inc.6$115
Jazz Pharmaceuticals Inc.4$109
Sanofi-aventis U.S. LLC1$100
Tesaro, Inc.3$98
Tersera Therapeutics LLC5$88
Blueprint Medicines Corporation3$71
G1 Therapeutics, Inc.3$70
Boehringer Ingelheim3$67
Puma Biotechnology, Inc.4$66
Teva Pharmaceuticals USA, Inc.4$64
Biocompatibles, Inc.3$63
Ipsen Biopharmaceuticals, Inc4$63
ADC Therapeutics America, Inc.3$58
Verastem, Inc.5$57
Sumitomo Pharma America, Inc.3$54
Mirati Therapeutics, Inc.3$52
Dendreon Pharmaceuticals LLC2$48
Servier Pharmaceuticals LLC2$46
Genmab U.S., Inc.2$46
Dova Pharmaceuticals3$40
Sobi, Inc2$38
CTI Biopharma Corp.2$34
Fennec Pharmaceuticals, Inc.2$32
Mylan Institutional Inc.2$29
Deciphera Pharmaceuticals Inc.1$27
Beone Medicines USA, Inc.1$24
Sun Pharmaceutical Industries Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,425 in reported general payments places this provider in the 50th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,411,958
Medicare patients
483
Services billed
145,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide145$2,093,845
BrukinsaZanubrutinib42$610,254
PomalystPomalidomide28$558,859
XpovioSelinexor13$406,140
CalquenceAcalabrutinib Maleate28$388,663
IbrancePalbociclib21$317,728
LenvimaLenvatinib Mesylate12$296,878
ImbruvicaIbrutinib12$183,942
Lenalidomide16$179,284
NubeqaDarolutamide12$163,716
NinlaroIxazomib Citrate12$137,691
SprycelDasatinib11$111,926
EliquisApixaban119$73,806
XareltoRivaroxaban63$48,179
Abiraterone Acetate22$38,901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$431$2,093,845145 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$492$670,78539 claims
Beigene USA, Inc.Brukinsa$1,416$610,25442 claims
Karyopharm Therapeutics Inc.Xpovio$2,045$406,14013 claims
PfizerIbrance, Eliquis$278$391,533140 claims
AstraZenecaCalquence$850$388,66328 claims
Eisai Inc.Lenvima$315$296,87812 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$184$183,94212 claims
BayerNubeqa$264$163,71612 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$211$137,69112 claims
Johnson & JohnsonXarelto$1,543$48,17963 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$64$1,25292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →